1. Dynamic HIV risk differentiation among youth: Validation of a tool for prioritization of prevention in East Zimbabwe.
- Author
-
Moorhouse LR, Gregson S, Imai-Eaton JW, Mayini J, Dadirai T, Magoge-Mandizvidza P, Maswera R, Mabaya S, Baggaley R, Low-Beer D, Nyamukapa C, and Dalal S
- Abstract
Background: Differentiating risk for HIV infection is important for providing focussed prevention options to individuals. We conducted a longitudinal study to validate a risk-differentiation tool for predicting HIV or HSV-2 acquisition among HIV-negative youth., Setting: Population-based household survey in east Zimbabwe., Methods: HIV and HSV-2 status and HIV behavioural risk factors were assessed in two surveys conducted 12 months apart among young people. Associations between risk-behaviours and combined HIV/HSV-2 incident infection were estimated using proportional hazards models. We calculated the sensitivity and specificity of risk-differentiation questions in predicting HIV/HSV-2 acquisition and quantified changes between surveys among low, medium, and high-risk categories., Results: In total, 44 HIV/HSV-2 seroconversions were observed in 1812 person-years of follow up (2.43/100PY, 95%CI: 1.71-3.15); 50% of incident cases reported never having had sex at baseline. Risk of HIV/HSV-2 acquisition was higher for those reporting non-regular partners (women: HR=2.71, 95% CI:1.12-6.54, men: HR=1.37, 95%CI: 0.29-6.38) and those reporting having a partner with a sexually transmitted infection (STI) (HR=7.62 (1.22-47.51). Adding a question on non-regular partnerships increased tool sensitivity from 18.2% to 38.6%, and further to 77.3% when restricted to those who had ever had sex. Individual risk category increased for 28% of men and 17% of women over 12-months., Conclusion: The refined risk differentiation tool identified a high proportion of youth at risk of HIV acquisition. Despite this, half of incident infections were among individuals who reported no prior sexual activity. The shifting patterns of risk behaviours underscore the need for dynamic prevention engagement strategies in high HIV prevalence or incidence settings., Competing Interests: Conflicts of Interest SG declares shareholdings in pharmaceutical companies GlaxoSmithKline and Astra Zeneca. All other authors have no conflicts of interest to declare. The WHO was involved in study design and data interpretation.
- Published
- 2024
- Full Text
- View/download PDF